Neutralizing Interleukin (IL)-6

NCT07493317 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: Tocilizumab

Sponsor

Icahn School of Medicine at Mount Sinai